What your cardiovascular patients' standard workup may be missing

This webinar is on-demand and can be viewed at your convenience.

An underrecognized, genetically inherited risk factor may be quietly accelerating cardiovascular disease in patients you're already treating — and routine workups won't catch it.

Lipoprotein(a), or Lp(a), has an emerging and increasingly documented role in aortic stenosis and peripheral arterial disease. Yet for many clinicians, it remains outside routine diagnostic consideration.

This on-demand session with physician leaders from University of Colorado and Duke University Health System closes that gap with evidence-grounded, practice-relevant guidance.

You will learn:

How Lp(a) contributes to the pathophysiology and progression of aortic stenosis and PAD
Prevalence and clinical significance of elevated Lp(a) in these patient populations
Current evidence linking Lp(a) to cardiovascular outcomes
Diagnostic strategies for identifying patients at elevated risk

Presenters:

Dr. Marc P. Bonaca MD, MPH, FACC, FAHA

Executive Director of Colorado Prevention Center, Aurora, CO, USA
Director of Vascular Research, Tenured Professor of Medicine, University of Colorado
Anschutz, Aurora, CO, USA
Chair of the AHA PAD Collaborative
Past Chair of the ACC Vascular Disease Section Leadership Council

Nishant Shah, MD

Assistant Professor, Medicine and Cardiovascular Disease Prevention
Lead for the Duke Health System Remote Lipid Monitoring Program
Clinical lead in the implementation of Inclisiran across Duke Health System
DCRI for a study that evaluates the effectiveness of PCSK9 inhibitors in the Prevention of
Cardiovascular Disease